USNA USANA Health Sciences, Inc. Common Stock
NYSE · Consumer products · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 13, 2026USNA Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
USNA Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 23 Kasım 2016 | 2-for-1 | İleri |
| 31 Ekim 2003 | 2-for-1 | İleri |
| 04 Ağustos 1998 | 2-for-1 | İleri |
USANA Health Sciences, Inc. Common Stock Hakkında Wikipedia'dan şirket genel bakışı
USANA Health Sciences, Inc., or USANA, is an American direct sales company based in Salt Lake City, Utah. As of 2021, USANA was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 25 countries via a network of independent distributors.
History
In 1992, immunologist and microbiologist Myron Wentz moved his diagnostic testing company, Gull Laboratories, from Salt Lake City to West Valley City, Utah, and spun it into USANA Health Services, a multilevel marketing manufacturer of supplements. Beginning in 1993, Dallin A. Larsen served as USANA's vice president of sales (and later as a consultant to USANA's president and special advisor to the board of directors) before founding the MLM beverage company Monavie in 2005. USANA's products are not available through retail channels, and can only be obtained through one of its brand partnersor by direct order through the company.
On 20 February 2007, Barry Minkow, founder of the Fraud Discovery Institute, distributed a 500-page report to officials at the U.S. Securities and Exchange Commission (SEC), the Federal Bureau of Investigation (FBI), and the Internal Revenue Service (IRS) accusing USANA of operating an illegal pyramid scheme. The SEC conducted an investigation into USANA's business practices in March 2007 and found no evidence of wrongdoing, concluding its inquiry with no enforcement action recommended. Minkow acknowledged that he was shorting USANA's shares, hoping to profit from a drop in the stock price. In April 2007, a class action lawsuit was filed alleging that USANA's common stock had been artificially inflated. In August 2007, USANA was notified by the Securities and Exchange Commission (SEC) that its shares were subject to delisting from the NASDAQ due to its Form 10-Q, and was determined to be in compliance that October.
In January 2008, a shareholder suit was filed with allegations that USANA had misled investors about the sustainability of its growth and business model. The cases were dismissed, and the company was cleared by the U.S. Securities and Exchange Commission after an informal inquiry into the allegations, stating that it did "not intend to recommend any enforcement action by the Commission." Later that year, two Canadian USANA distributors were awarded $7 million in damages for their wrongful dismissal from the company. The firm had terminated their positions in 2003 because it believed the distributor had violated the companies' policies and procedures.
USANA filed suits against Minkow and his company claiming defamation and stock manipulation. USANA dropped the defamation suit and in March 2008 U.S. District Judge Tena Campbell threw out four of the five claims brought by USANA against Minkow ruling that USANA's claims violated California's anti-SLAPP law for suing Minkow for fair criticism and that USANA did not show a reasonable probability of winning on those claims. The remaining charge of stock manipulation was settled in July 2008, when USANA and Minkow reached an undisclosed settlement that included the removal of all USANA-related materials from the Fraud Discovery Institute website, a related Chinese website, and YouTube. Minkow also agreed to never trade in USANA's stock again.
In December 2010, USANA completed the application process to transfer its common stock listing from the NASDAQ National Market System, where it had traded since 1996, to the New York Stock Exchange. The transfer became official at the beginning of 2011. It received drug-establishment registration from the Food and Drug Administration to manufacture over-the-counter drugs later that year. In 2012, 91% of product sales were purchased by associates. The company acquired BabyCare Ltd., a China-based prenatal supplement company, in 2013 and announced plans to build a manufacturing facility in the country.
By 2018, USANA had reported record revenue due to growth in the Asia-Pacific region, though it recorded a 7% drop in net sales during its 2019 annual report. USANA has partnered with HealthCorps on health education for children and, in 2019, the USANA Foundation's Kids Eat program opened a facility to pack and distribute food for childhood hunger in the Utah area. In 2026, the Kids Eat program continued efforts to address childhood food insecurity in Utah by providing food bags to students and allowing businesses, families, and other organizations to sponsor participating schools. It was also announced as the official nutritional partner of the Spartan Race endurance brand in the United States. Its sales for the first quarter of 2020 declined by 2.3 percent compared with 2019 numbers.
The USANA Foundation was founded in 2012 and has provided hundreds of millions of meals in more than 45 countries. Their programs include USANA Kids Eat and the USANA Garden Towers.
In February 2019, the Ministry of Commerce in China suspended operations of all multi-level marketing companies and participants to conduct a 100-day review of the country's health foods industry due to exaggerated advertising claims and questionable products in the unregulated sector. Chinese departments initiated "Hundred Days of Action" to clean up the health market, where 49 products from various companies were revoked, 54 food business licenses of various companies were revoked, 90 business licenses of various companies were revoked, and 465 counterfeit and fake dens were destroyed. 85 companies, including BabyCare Ltd., a USANA subsidiary, signed a declaration to self-discipline and regulate operations, with BabyCare speaking at an event hosted by the Chinese government.
In 2024, USANA acquired a 79% stake in children's health and wellness company Hiya Health in a $260 million transaction, making Hiya a subsidiary of USANA. At the time of the acquisition, Hiya had grown to approximately $100 million in annual sales and offered eight children's health products, including multivitamins, probiotics, iron supplements, and immune support products.
Corporate affairs
Leadership
In 2007, USANA faced repeated controversy after members of its board of directors, medical advisory board and several of its executives made false statements regarding their qualifications, including education and licenses.
Founder Myron Wentz was the company's chief executive officer from 1992 until 2008, when his son, Dave Wentz, succeeded him after working in positions such as president, executive vice president, and senior vice president of strategic development. In 2015, USANA announced that the chief executive officer role would be divided between Wentz and Kevin Guest, with the former taking global operations and the latter, field development and sales. Guest was appointed the sole chief executive officer in November 2016.
Operations
USANA, a multilevel marketing company, sells its products primarily through non-employee Brand Partners, as well as through the Internet. The firm's 2010 income disclosure statement defines "associates" as those who are actively building a business, acting as wholesale buyers, or are new distributors. The firm's 2009 SEC 10-K filing distinguishes between associates and preferred customers. Associates are independent distributors of USANA products and also purchase them for personal use. Preferred customers may purchase products at wholesale prices strictly for personal use and are not permitted to resell or distribute them. As of July 2011, the firm had 222,000 active Associates and 68,000 preferred customers. It manufactured 90% of its products at the Salt Lake City headquarters, which produced more than 22 million tablets each week.
Associates may be eligible to receive commissions based on their own product sales as well as through sales made by any new distributors they recruit. According to documentation from USANA corporate, 87 percent of associates fail to make enough from commissions to recover the cost of their qualifying purchases with 67 percent of all associates making no commission; the top 2.31 percent of associates earns 72.2 percent of the company's commissions. According to a 2011 article published by the Salt Lake City Tribune, the firm's FY09 income disclosure statement indicated that the average yearly income of the company's 165,710 associates, which includes those just starting, was $617, while the "top-of-the-pyramid distributors earn an average of $857,865 annually".
USANA sells nutritional, personal care, and food products through Brand Partners and online channels.
USANA classifies Brand Partners and Preferred Customers in its core nutritional business as active customers. There were 387,000 active customers as of January 2026. In 2025, Brand Partners and Preferred Customers each made up about half of all active customers.
Sponsorships
USANA has been a paid sponsor of various athletic organizations. USANA offers an "Athlete Guarantee Program" to select sponsored athletes. The program permits selected participants to enter into an agreement with the company stipulating that, should an athlete enrolled in the program test positive for a banned substance (included in World Anti-Doping Agency regulations) as a result of taking USANA products, the company will compensate the athlete up to two times his or her current annual earnings up to $1 million USD.
In 2006, USANA signed a co-sponsorship agreement with the WTA Tour and extended it in 2011. The agreement provides athletes with nutritional supplements that are guaranteed to conform to the Tour's antidoping policy. As part of the agreement in 2011, USANA donated $1 to Children's Hunger Fund for every ace scored at a WTA tournament beginning at Wimbledon and continuing through the end of the season. USANA provided its products to 40 athletes at the Turin Olympics and worked with various sports organizations, including the Professional Rodeo Cowboys Association.
In 2003, USANA became the title sponsor of the USANA Amphitheatre, an outdoor amphitheatre based in West Valley City, Utah with a seating capacity of 20,000. In May 2012, United Concerts announced a continued naming rights partnership with USANA Health Sciences through March 2018.
In 2020, USANA became the title partner of U.S. Ski & Snowboard's training and education facility, the Center of Excellence. The facility is a training hub used by Olympians, youth athletes, and various international competitions.
In the lead-up to the 2020 Summer Olympics, USANA announced partnerships with USA Swimming and the USA Skateboarding National Team. It was the official multivitamin sponsor of USA Swimming and official nutritional supplement supplier of USA Skateboarding. The partnerships reportedly extended into multi-year agreements.
Products
USANA produces three product lines: USANA Nutritionals (Cellsentials, Optimizers, and Digestion/Detox nutritional supplements), USANA Diet & Energy (Reset meal replacement shakes, protein bars, and Rev3 energy drinks), and Sensé & Celavive personal care (skin care, skin treatment, and hair & body care products).
USANA Essentials were tested in 2011 by ConsumerLab.com in its Multivitamin and Multimineral Supplements Review of 38 leading multivitamin/multimineral products sold in the U.S. and Canada. The Essentials passed ConsumerLab's test, which included testing of selected index elements, their ability to disintegrate in solution per United States Pharmacopeia guidelines, lead contamination threshold set in California Proposition 65, and meeting U.S. Food and Drug Administration (FDA) labeling requirements.
USANA began using InCelligence Technology in August 2016 and registered it as a U.S. trademark in March 2017. The technology is used in the company's CellSentials nutritional supplement system, including its Core Minerals and Vita-Antioxidant products, which USANA markets as using its InCelligence Complex to support cellular protection and renewal. As of 2019, its products are marketed in the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Netherlands, the United Kingdom, the Caribbean, Puerto Rico, Philippines, France, China, Spain, Italy, Germany, Romania, Denmark, Colombia and Indonesia.
Reception
From 2004 to 2006, USANA was named on Forbes "200 Best Small Companies" list. In 2007, a Forbes article quoted industry experts and government officials who had raised questions about the cost of USANA's supplements and its business practices. Radio-Canada later aired an investigative report that examined the company's products, pricing and "misleading income claims" made to potential associates concerning revenue. It included hidden-camera footage of recruitment and other sessions, which found one group of associates appeared to violate the company's policies and distributor agreements. This contrasted with the Canadian legal requirements for multi-level marketing companies to provide clear, frequent and complete information about the revenue of the typical participant. In addition, the same group of associates were filmed making recommendations for using USANA products to treat illnesses including leukemia.
John Cloud, senior writer for Time Magazine, evaluated nutritional supplements in which he took a regimen of USANA pills, protein bars, powder drinks and psyllium fiber as recommended by the company's online evaluation. Cloud took a blood test before starting the products to measure levels of calcium, protein, sodium, cholesterol, glucose, and other substances, and was then tested again five months after starting the supplement regimen, which included 3,000 pills at a cost of $1,200. The follow-up test revealed a change in only two values; a 75% increase in vitamin D levels (attributed to the vitamin D3 supplement Cloud had been taking) and a 28 mg/dl increase in high-density lipoprotein, which could not be accounted for. Cloud also experienced a placebo response where that act of taking the supplements made him feel more vigorous despite no physiological reasons being present. This response also led to a 10-lb weight gain, as the belief that he was more vigorous led him to make poorer dietary decisions—a phenomenon referred to as the "licensing effect".
New Zealand government statistician for the Commerce Commission, Murray H. Smith, who served as an expert witness in every pyramid scheme case brought by the Commission preceding 10 years, opined in 2008 that very few USANA distributors are likely to become wealthy, and stated, "you can make a very strong argument that this could be a pyramid scheme." When asked by the National Business Review to review the firm's business structure and compensation plan, it was Smith's opinion, from a statistical not legal standpoint, that the firm demonstrated a number of characteristics commonly occurring in pyramid schemes including that most members recoup less than what they pay to participate; that those at the top of the structure are more likely to make more than those on the bottom of the structure; and that as the company grows it will become harder to recruit others. Smith also noted the company's significant turnover in distributors making it necessary to continually recruit.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | USNA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -7.15Y ort. ≈19.7 | ≈19.7 | · | · | |
| F/S (TTM) | 0.35Y ort. ≈1.0 | ≈1.0 | 1.2 | Düşük değerli | |
| F/D (MRQ) | 0.55Y ort. ≈2.3 | ≈2.3 | 2.4 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | -16.85Y ort. ≈20.5 | ≈20.5 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -157.25Y ort. ≈13.5 | ≈13.5 | 16.8 | Adil değer | |
| Fiyat / Maddi Defter Değeri (MRQ) | 0.75Y ort. ≈3.0 | ≈3.0 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | USNA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Brüt Kar Marjı (TTM) | 76.7%5Y ort. ≈80.5% | ≈80.5% | 66.5% | En üst düzey | |
| Faaliyet Kâr Marjı (TTM) | -1.7%5Y ort. ≈9.4% | ≈9.4% | 3.5% | Zayıf | |
| FAVÖK Marjı (TTM) | 2.3%5Y ort. ≈11.2% | ≈11.2% | 3.5% | Zayıf | |
| Vergi Öncesi Kar Marjı (TTM) | -1.5%5Y ort. ≈10.0% | ≈10.0% | 4.1% | Zayıf | |
| Net Kâr Marjı (TTM) | -4.2%5Y ort. ≈6.0% | ≈6.0% | 3.1% | Zayıf | |
| ROA (TTM) | -5.5%5Y ort. ≈9.8% | ≈9.8% | 6.7% | Zayıf | |
| ROE (TTM) | -7.4%5Y ort. ≈13.8% | ≈13.8% | 7.0% | Ortalamanın altında | |
| ROIC | 1.9%5Y ort. ≈13.1% | ≈13.1% | 7.9% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | USNA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 2.75Y ort. ≈2.5 | ≈2.5 | 2.6 | Aynı seviyede | |
| Quick Ratio (Cari Oran) | 1.25Y ort. ≈1.8 | ≈1.8 | 1.2 | Güçlü likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | USNA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 8.3%5Y ort. ≈-3.6% | ≈-3.6% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -2.5%5Y ort. ≈-6.5% | ≈-6.5% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | -4.0% | · | · | · | |
| EPS YoY (EPS YB) | -73.5%5Y ort. ≈-31.0% | ≈-31.0% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | -74.4%5Y ort. ≈-32.7% | ≈-32.7% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -45.5%5Y ort. ≈-30.1% | ≈-30.1% | · | · | |
| EPS CAGR 5Y (EPS Bileşik Yıllık Büyüme Oranı 5Y) | -37.0% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -46.3%5Y ort. ≈-31.7% | ≈-31.7% | · | · | |
| Net Income CAGR 5Y (Net Gelir Bileşik Yıllık Büyüme Oranı 5Y) | -38.7% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | USNA | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 1.25Y ort. ≈1.5 | ≈1.5 | 1.5 | Zayıf | |
| Inventory Turnover (Stok Devir Hızı) | 2.35Y ort. ≈2.4 | ≈2.4 | 3.2 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$589.3K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Tem 20, 2026 | $-0.07 | $0.44 | -116.0% |
| 31 Mart 2026 | $0.61 | $0.45 | 35.9% | |
| 31 Aralık 2025 | $0.60 | $0.42 | 43.5% | |
| 30 Eylül 2025 | $-0.15 | $0.48 | -131.3% | |
| 30 Haziran 2025 | $0.74 | $0.55 | 34.4% | |
| 31 Mart 2025 | $0.73 | $0.71 | 2.2% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925M | $855M | $921M | $999M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B | $918M | $790M | |
| Cost of Revenue | $201M | $161M | $177M | $194M | $218M | $209M | $188M | $201M | $179M | $180M | $160M | $141M | |
| Gross Profit | $724M | $693M | $744M | $805M | $969M | $926M | $873M | $989M | $868M | $826M | $759M | $650M | |
| R&D Expense | $11M | $12M | $11M | $12M | $11M | $11M | $10M | $10M | $9M | $9M | $6M | $5M | |
| SG&A Expense | $337M | $263M | $257M | $262M | $279M | $261M | $268M | $275M | $265M | $234M | $209M | $185M | |
| Operating Expenses | $687M | $627M | $651M | $697M | $798M | $749M | $727M | $800M | $735M | $687M | $617M | $534M | |
| Operating Income | $37M | $66M | $93M | $108M | $170M | $176M | $146M | $188M | $133M | $139M | $142M | $116M | |
| Interest Expense | · | · | $262.0K | $192.0K | $57.0K | $507.0K | $66.0K | $36.0K | $46.0K | $444.0K | $15.0K | $129.0K | |
| Interest Income | $2M | $11M | $10M | $4M | $3M | $3M | $5M | $4M | $2M | $1M | $1M | $500.0K | |
| Other Non-op | $3M | $-1M | $7.0K | $-3M | $-2M | $-571.0K | $-335.0K | $-1M | $-3.0K | $-1M | $-174.0K | $-820.0K | |
| Pretax Income | $42M | $76M | $102M | $109M | $171M | $178M | $150M | $192M | $135M | $139M | $143M | $116M | |
| Income Tax | $30M | $34M | $39M | $39M | $54M | $53M | $50M | $65M | $72M | $39M | $48M | $39M | |
| Net Income | $11M | $42M | $64M | $69M | $117M | $125M | $101M | $126M | $63M | $100M | $95M | $77M | |
| EPS (Basic) | $0.58 | $2.20 | $3.31 | $3.60 | $5.78 | $5.89 | $4.44 | $5.24 | $2.57 | $4.14 | $3.72 | $2.90 | |
| EPS (Diluted) | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 | $3.59 | $2.80 | |
| Shares (Basic) | 18,535,000 | 19,103,000 | 19,250,000 | 19,254,000 | 20,146,000 | 21,156,000 | 22,644,000 | 24,105,000 | 24,349,000 | 24,185,000 | 25,460,000 | 26,443,000 | |
| Shares (Diluted) | 18,574,000 | 19,162,000 | 19,345,000 | 19,310,000 | 20,343,000 | 21,256,000 | 22,818,000 | 24,642,000 | 24,708,000 | 25,047,000 | 26,355,000 | 27,377,000 | |
| EBITDA | $70M | $81M | $106M | $121M | $183M | $190M | $161M | $205M | $149M | $152M | $152M | $125M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $158M | $182M | $330M | $288M | $240M | $312M | $235M | $214M | $247M | $176M | $143M | $111M | |
| Receivables | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $103M | $70M | $61M | $67M | $98M | $90M | $69M | $82M | $63M | $65M | $66M | $45M | |
| Prepaid Expense | $23M | $28M | $26M | $29M | $27M | $23M | $26M | $33M | $30M | $37M | $35M | $35M | |
| Other Current Assets | $5M | $5M | $6M | $7M | $4M | $5M | $5M | $7M | $5M | $6M | $5M | $6M | |
| Current Assets | $288M | $279M | $418M | $384M | $365M | $425M | $329M | $392M | $340M | $278M | $244M | $191M | |
| PP&E (Net) | $94M | $95M | $100M | $98M | $102M | $100M | $95M | $92M | $103M | $101M | $88M | $71M | |
| PP&E (Gross) | · | · | $212M | $210M | $211M | $199M | $181M | $178M | $177M | $164M | $120M | $114M | |
| Accum. Depreciation | $135M | $130M | $129M | $125M | $122M | $116M | $105M | $96M | $86M | $76M | $71M | $64M | |
| Goodwill | $138M | $144M | $17M | $17M | $18M | $17M | $17M | $17M | $17M | $17M | $17M | $18M | |
| Intangibles | $133M | $152M | $30M | $32M | $30M | $31M | $30M | $32M | $35M | $34M | $38M | $41M | |
| Other Non-current Assets | $62M | $59M | $55M | $55M | $58M | $62M | $43M | $18M | $21M | $22M | $25M | $24M | |
| Total Assets | $743M | $748M | $633M | $597M | $578M | $641M | $517M | $554M | $519M | $471M | $423M | $351M | |
| Accounts Payable | $17M | $12M | $10M | $11M | $14M | $18M | $13M | $10M | $12M | $9M | $10M | $8M | |
| Accrued Liabilities | $10M | $14M | $10M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $129M | $140M | $119M | $144M | $161M | $168M | $136M | $149M | $141M | $138M | $131M | $109M | |
| Capital Leases | $12M | $10M | $5M | $8M | $10M | · | $17M | · | · | · | · | · | |
| Deferred Tax | $5M | $4M | $5M | $4M | $7M | $12M | $10M | $13M | $14M | $5M | $10M | $11M | |
| Other Non-current Liabilities | $23M | $18M | $12M | $14M | $14M | $19M | $19M | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $157M | $162M | $136M | · | · | · | · | · | · | · | · | · | |
| Common Stock | $18.0K | $19.0K | $19.0K | $19.0K | $19.0K | $21.0K | $22.0K | $24.0K | $24.0K | $24.0K | $25.0K | $13.0K | |
| Retained Earnings | $466M | $479M | $445M | $392M | $345M | $383M | $306M | $330M | $288M | $265M | $215M | $166M | |
| AOCI | $-16M | $-23M | $-14M | $-13M | $458.0K | $-4M | $-14M | $-10M | $-1M | $-12M | $-4M | $2M | |
| Stockholders' Equity | $533M | $532M | $497M | $434M | $395M | $442M | $352M | $391M | $363M | $325M | $281M | $230M | |
| Liabilities + Equity | $743M | $748M | $633M | $597M | $578M | $641M | $517M | $554M | $519M | $471M | $423M | $351M | |
| Shares Outstanding | 18,281,000 | 19,064,000 | 19,130,000 | 19,206,000 | 19,393,000 | 21,038,000 | 21,655,000 | 23,567,000 | 24,024,000 | 24,485,000 | 24,976,000 | 25,266,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $33M | $15M | $13M | $13M | $13M | $14M | $15M | $17M | $16M | $13M | $10M | $9M | |
| Stock-based Comp | $14M | $15M | $15M | $13M | $14M | $14M | $16M | $15M | $15M | $17M | $11M | $10M | |
| Deferred Tax | $-7M | $-7M | $-3M | $-7M | $-3M | $-2M | $-4M | $607.0K | $19M | $-4M | $-3M | $-1M | |
| Amort. of Intangibles | $19M | $2M | $2M | $2M | $1M | $1M | $1M | $2M | $1M | $2M | $900.0K | $431.0K | |
| Restructuring | $6M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-28M | $-3M | $-18M | $15M | $-20M | $10M | $-442.0K | $-7M | $10M | $11M | $-2M | $11M | |
| Operating Cash Flow | $22M | $61M | $71M | $104M | $121M | $160M | $127M | $152M | $124M | $137M | $111M | $105M | |
| CapEx | $14M | $10M | $14M | $10M | $13M | $15M | $17M | $11M | $13M | $33M | $24M | $20M | |
| Investing Cash Flow | $-10M | $-213M | $-12M | $-12M | $-14M | $-34M | $47M | $-69M | $-13M | $-32M | $-25M | $-16M | |
| Stock Repurchased | $28M | $9M | $12M | $25M | $178M | $57M | $150M | $105M | $50M | $65M | $61M | $139M | |
| Net Stock Activity | $-28M | $-9M | $-12M | $-25M | $-178M | $-57M | $-150M | $-105M | $-50M | $-65M | $-61M | $-139M | |
| Financing Cash Flow | $-41M | $10M | $-14M | $-30M | $-181M | $-59M | $-152M | $-105M | $-50M | $-65M | $-49M | $-113M | |
| Net Change in Cash | $-23M | $-149M | $42M | $48M | $-72M | $78M | $20M | $-33M | $72M | $32M | $32M | $-26M | |
| Taxes Paid | $37M | $40M | $42M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $9M | $51M | $56M | $94M | $108M | $145M | $110M | $141M | $111M | $104M | $88M | $85M | |
| Levered FCF | · | · | $56M | $93M | $108M | $145M | $110M | $141M | $111M | $104M | $88M | $85M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% | 81.6% | 82.3% | 83.1% | 82.9% | 82.1% | 82.6% | 82.2% | |
| Operating Margin | 4.0% | 7.8% | 10.1% | 10.8% | 14.3% | 15.6% | 13.8% | 15.8% | 12.7% | 13.8% | 15.4% | 14.7% | |
| Net Margin | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% | 10.3% | 9.7% | |
| Pretax Margin | 4.5% | 8.9% | 11.1% | 10.9% | 14.4% | 15.7% | 14.2% | 16.1% | 12.9% | 13.8% | 15.5% | 14.6% | |
| EBITDA Margin | 7.6% | 9.5% | 11.5% | 12.1% | 15.4% | 16.8% | 15.2% | 17.2% | 14.2% | 15.1% | 16.5% | 15.8% | |
| ROA | 1.4% | 6.1% | 10.4% | 11.8% | 19.1% | 21.5% | 18.8% | 23.5% | 12.6% | 22.4% | 24.5% | 21.3% | |
| ROE | 2.0% | 7.9% | 13.2% | 16.4% | 29.3% | 30.0% | 30.2% | 30.5% | 17.2% | 33.0% | 37.0% | 31.2% | |
| ROIC | 1.9% | 6.9% | 11.7% | 15.8% | 29.4% | 28.0% | 27.8% | 31.7% | 16.9% | 30.8% | 33.5% | 33.4% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.0 | 3.5 | 2.7 | 2.3 | 2.5 | 2.4 | 2.6 | 2.4 | 2.0 | 1.9 | 1.8 | |
| Quick Ratio | 1.2 | 1.3 | 2.8 | 2.0 | 1.5 | 1.9 | 1.7 | 1.4 | 1.8 | 1.3 | 1.1 | 1.0 | |
| Interest Coverage | · | · | 355.2 | 560.5 | 2985.8 | 348.1 | 2215.0 | 5232.0 | 2880.5 | 312.2 | 9444.1 | 900.0 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.2 | 1.5 | 1.7 | 1.9 | 2.0 | 2.0 | 2.2 | 2.1 | 2.3 | 2.4 | 2.2 | |
| Inventory Turnover | 2.3 | 2.5 | 2.7 | 2.3 | 2.3 | 2.2 | 2.5 | 2.8 | 2.8 | 2.8 | 2.9 | 3.0 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $29.16 | $27.91 | $25.99 | $22.62 | $20.37 | $20.99 | $16.24 | $16.60 | $15.12 | $13.29 | $22.49 | $18.22 | |
| Revenue / Share | $49.81 | $44.59 | $47.61 | $51.71 | $58.32 | $53.38 | $46.49 | $48.26 | $42.39 | $40.17 | $69.70 | $57.74 | |
| Cash Flow / Share | $1.20 | $3.18 | $3.65 | $5.38 | $5.96 | $7.55 | $5.55 | $6.17 | $5.01 | $5.47 | $8.46 | $7.68 | |
| Cash / Share | $8.66 | $9.53 | $17.27 | $15.02 | $12.37 | $14.83 | $10.84 | $9.09 | $10.29 | $7.18 | $11.47 | $8.80 | |
| EPS (TTM) | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 | $3.59 | $2.80 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.3% | -7.2% | -7.8% | -15.8% | 4.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -2.5% | -10.4% | -6.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -4.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -73.5% | -33.6% | -8.1% | -37.4% | -2.2% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -45.5% | -27.4% | -17.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -37.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -74.4% | -34.1% | -8.0% | -40.5% | -6.5% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -46.3% | -28.8% | -20.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -38.7% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $925M | $855M | $921M | $999M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B | $918M | $790M | |
| Net Income TTM | $11M | $42M | $64M | $69M | $117M | $125M | $101M | $126M | $63M | $100M | $95M | $77M | |
| Market Cap | $355M | $680M | $1.03B | $1.02B | $1.96B | $1.62B | $1.73B | $2.71B | $1.78B | $1.50B | $798M | $646M | |
| P/E | 33.5 | 16.3 | 16.2 | 14.8 | 17.7 | 13.2 | 18.1 | 22.5 | 29.3 | 15.3 | 17.8 | 18.3 | |
| P/S | 0.4 | 0.8 | 1.1 | 1.0 | 1.7 | 1.4 | 1.6 | 2.3 | 1.7 | 1.5 | 0.9 | 0.8 | |
| P/B | 0.7 | 1.3 | 2.1 | 2.4 | 5.0 | 3.7 | 4.9 | 6.9 | 4.9 | 4.6 | 2.8 | 2.8 | |
| P / Tangible Book | 1.4 | 2.9 | 2.3 | 2.7 | 5.7 | 4.1 | · | · | · | · | · | · | |
| P / Cash Flow | 15.9 | 11.2 | 14.5 | 9.8 | 16.2 | 10.1 | 13.7 | 17.8 | 14.4 | 10.9 | 7.2 | 6.1 | |
| P / FCF | 41.7 | 13.4 | 18.3 | 10.9 | 18.1 | 11.2 | 15.7 | 19.3 | 16.1 | 14.4 | 9.1 | 7.6 | |
| Earnings Yield | 3.0% | 6.1% | 6.2% | 6.8% | 5.7% | 7.6% | 5.5% | 4.5% | 3.4% | 6.5% | 5.6% | 5.5% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $223M | $250M | $240M | $214M | $236M | $250M | $214M | $200M | $213M | $228M | $221M | $213M | $248M | $153M | |
| Cost of Revenue | $48M | $59M | $59M | $49M | $50M | $52M | $39M | $39M | $40M | $43M | $42M | $43M | $49M | $35M | |
| Gross Profit | $175M | $191M | $181M | $165M | $186M | $197M | $175M | $161M | $173M | $185M | $179M | $171M | $200M | $118M | |
| SG&A Expense | $82M | $88M | $103M | $86M | $82M | $91M | $73M | $61M | $64M | $64M | $59M | $63M | $67M | $55M | |
| Operating Expenses | $195M | $177M | $191M | $164M | $169M | $181M | $167M | $145M | $155M | $160M | $155M | $153M | $173M | $117M | |
| Operating Income | $-20M | $14M | $-11M | $1M | $17M | $16M | $8M | $16M | $18M | $25M | $24M | $18M | $27M | $984.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $52.0K | · | $43.0K | $31.0K | · | |
| Interest Income | $595.0K | $437.0K | $-2M | $578.0K | $619.0K | $723.0K | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | |
| Other Non-op | $501.0K | $1M | $113.0K | $41.0K | $2M | $756.0K | $-390.0K | $-86.0K | $-349.0K | $-186.0K | $-368.0K | $234.0K | $-88.0K | $-852.0K | |
| Pretax Income | $-19M | $15M | $-13M | $2M | $19M | $17M | $10M | $19M | $20M | $27M | $27M | $21M | $29M | $2M | |
| Income Tax | $9M | $9M | $6M | $8M | $8M | $7M | $6M | $8M | $10M | $11M | $10M | $9M | $10M | $5M | |
| Net Income | $-21M | $8M | $-19M | $-7M | $10M | $9M | $4M | $11M | $10M | $17M | $17M | $11M | $18M | $-3M | |
| EPS (Basic) | $-1.16 | $0.41 | $-0.99 | $-0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.55 | $0.86 | $0.87 | $0.59 | $0.95 | $-0.03 | |
| EPS (Diluted) | $-1.16 | $0.41 | $-0.99 | $-0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.54 | $0.86 | $0.87 | $0.59 | $0.95 | $-0.01 | |
| Shares (Basic) | 18,486,000 | 18,398,000 | · | 18,293,000 | 18,513,000 | 19,049,000 | · | 19,078,000 | 19,073,000 | 19,174,000 | · | 19,245,000 | 19,283,000 | · | |
| Shares (Diluted) | 18,486,000 | 18,411,000 | · | 18,293,000 | 18,536,000 | 19,085,000 | · | 19,083,000 | 19,159,000 | 19,302,000 | · | 19,372,000 | 19,328,000 | · | |
| EBITDA | $-12M | $22M | · | $9M | $24M | $24M | · | $16M | $18M | $28M | · | $18M | $30M | · |
Bilanço
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $169M | $163M | $158M | $145M | $151M | $180M | $182M | $365M | $332M | $328M | $330M | $307M | $295M | $288M | |
| Receivables | $3M | $10M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $86M | $96M | $103M | $91M | $83M | $74M | $70M | $64M | $62M | $61M | · | $60M | $64M | · | |
| Prepaid Expense | $23M | $25M | $27M | $28M | $27M | $28M | $28M | $22M | $25M | $32M | · | $23M | $36M | · | |
| Other Current Assets | · | · | $5M | · | · | · | $5M | · | · | · | · | · | · | · | |
| Current Assets | $281M | $294M | $288M | $264M | $262M | $281M | $279M | $451M | $419M | $421M | · | $390M | $396M | · | |
| PP&E (Net) | $94M | $95M | $94M | $96M | $97M | $94M | $95M | $98M | $98M | $98M | · | $95M | $97M | · | |
| Accum. Depreciation | · | · | $135M | · | · | · | $130M | · | · | · | · | · | · | · | |
| Goodwill | $109M | $138M | $138M | $144M | $144M | $144M | $144M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | |
| Intangibles | $125M | $129M | $133M | $138M | $143M | $147M | $152M | $29M | $29M | $29M | · | $29M | $32M | · | |
| Other Non-current Assets | $65M | $58M | $62M | $60M | $63M | $61M | $59M | $59M | $51M | $53M | · | $54M | $56M | · | |
| Total Assets | $703M | $739M | $743M | $727M | $735M | $747M | $748M | $671M | $631M | $629M | · | $601M | $606M | · | |
| Accounts Payable | $15M | $16M | $17M | $16M | $18M | $14M | $12M | $7M | $7M | $8M | · | $9M | $11M | · | |
| Accrued Liabilities | · | · | $10M | · | · | · | $14M | · | · | · | · | · | · | · | |
| Current Liabilities | $106M | $117M | $129M | $119M | $122M | $137M | $140M | $115M | $104M | $113M | · | $113M | $130M | · | |
| Capital Leases | · | · | $12M | · | · | · | $10M | · | · | · | · | · | · | · | |
| Deferred Tax | $5M | $5M | $5M | $4M | $5M | $5M | $4M | $5M | $5M | $5M | · | $5M | $6M | · | |
| Other Non-current Liabilities | $22M | $22M | $23M | $22M | $23M | $21M | $18M | $19M | $11M | $12M | · | $13M | $14M | · | |
| Total Liabilities | $132M | $144M | $157M | $145M | $149M | $163M | $162M | · | · | · | · | · | · | · | |
| Common Stock | $18.0K | $18.0K | $18.0K | $18.0K | $18.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | · | $19.0K | $19.0K | · | |
| Retained Earnings | $452M | $473M | $466M | $467M | $474M | $478M | $479M | $474M | $464M | $453M | · | $428M | $410M | · | |
| AOCI | $-14M | $-14M | $-16M | $-19M | $-19M | $-23M | $-23M | $-14M | $-21M | $-19M | · | $-20M | $-11M | · | |
| Stockholders' Equity | $526M | $544M | $533M | $528M | $531M | $530M | $532M | $533M | $512M | $500M | $497M | $470M | $455M | $434M | |
| Liabilities + Equity | $703M | $739M | $743M | $727M | $735M | $747M | $748M | $671M | $631M | $629M | · | $601M | $606M | · | |
| Shares Outstanding | 18,463,000 | 18,457,000 | 18,281,000 | 18,272,000 | 18,262,000 | 18,786,000 | 19,064,000 | 19,056,000 | 19,051,000 | 19,047,000 | 19,130,000 | 19,122,000 | 19,294,000 | 19,206,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $8M | $8M | $13M | $8M | $8M | $8M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | |
| Stock-based Comp | $3M | $3M | $3M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | $4M | |
| Other Non-cash | · | · | · | · | · | $-5M | · | · | · | $-6M | · | · | $-12M | · | |
| Operating Cash Flow | $23M | $10M | $-33M | $-2M | $12M | $15M | $6M | $28M | $8M | $18M | $26M | $22M | $13M | $40M | |
| CapEx | $3M | $3M | $6M | $3M | $5M | $3M | $2M | $441.0K | $3M | $3M | $7M | $1M | $2M | $3M | |
| Investing Cash Flow | $-4M | $-3M | $-2M | $-3M | $-4M | $-4M | $-205M | $85.0K | $-2M | $-4M | $-7M | $-1M | $-3M | $-3M | |
| Stock Repurchased | $0 | $0 | $18M | $0 | $15M | $12M | $0 | $-18M | $0 | $9M | $0 | $12M | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $-12M | · | · | · | $-9M | · | · | $0 | · | |
| Financing Cash Flow | $-14M | $-4M | $-27M | $-979.0K | $-39M | $-14M | $23M | $40M | $-1M | $-12M | $658.0K | $-12M | $-3M | $-150.0K | |
| Net Change in Cash | $6M | $4M | $-58M | $-6M | $-28M | $-2M | $-183M | $65M | $4M | $-2M | $23M | $7M | $7M | $41M | |
| Free Cash Flow | · | $7M | · | · | · | $13M | · | · | · | $14M | · | · | $11M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $14M | · | · | $11M | · |
Kârlılık
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 76.2% | · | 77.1% | 78.7% | 79.0% | · | 80.4% | 81.0% | 81.1% | · | 80.1% | 80.5% | · | |
| Operating Margin | -9.0% | 5.5% | · | 0.57% | 7.1% | 6.3% | · | 7.8% | 8.4% | 10.8% | · | 8.2% | 10.8% | · | |
| Net Margin | -9.6% | 3.0% | · | -3.0% | 4.1% | 3.8% | · | 5.3% | 4.9% | 7.3% | · | 5.3% | 7.4% | · | |
| Pretax Margin | -8.5% | 6.2% | · | 0.84% | 8.0% | 6.7% | · | 9.3% | 9.5% | 11.9% | · | 9.6% | 11.5% | · | |
| EBITDA Margin | -5.5% | 8.8% | · | 4.3% | 10.4% | 9.6% | · | 7.8% | 8.4% | 12.2% | · | 8.2% | 12.1% | · | |
| ROA | -3.0% | 1.0% | · | -0.93% | 1.4% | 1.4% | · | 1.7% | 1.7% | 2.7% | · | 2.0% | · | · | |
| ROE | -4.0% | 1.4% | · | -1.2% | 1.8% | 1.8% | · | 2.1% | 2.1% | 3.5% | · | 2.6% | · | · | |
| ROIC | -5.6% | 1.1% | · | -0.86% | 1.8% | 1.6% | · | 1.7% | 1.8% | 3.0% | · | 2.1% | · | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 2.5 | · | 2.2 | 2.2 | 2.0 | · | 3.9 | 4.0 | 3.7 | · | 3.5 | · | · | |
| Quick Ratio | 1.6 | 1.5 | · | 1.2 | 1.2 | 1.3 | · | 3.2 | 3.2 | 2.9 | · | 2.7 | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 474.5 | · | 409.5 | 866.0 | · |
Verimlilik
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.3 | 0.3 | 0.4 | · | 0.4 | · | · | |
| Inventory Turnover | 0.6 | 0.7 | · | 0.6 | 0.7 | 0.8 | · | 0.6 | 0.7 | 0.7 | · | 0.7 | · | · | |
| Receivables Turnover | 133.8 | 51.8 | · | · | · | · | · | · | · | · | · | · | · | · |
Hisse Başına
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $28.51 | $29.45 | · | $28.90 | $29.08 | $28.20 | · | $27.97 | $26.89 | $26.25 | · | $24.60 | · | · | |
| Revenue / Share | $12.08 | $13.59 | · | $11.68 | $12.72 | $13.08 | · | $10.49 | $11.11 | $11.80 | · | $11.01 | $12.85 | · | |
| Cash Flow / Share | · | $0.53 | · | · | · | $0.81 | · | · | · | $0.92 | · | · | $0.66 | · | |
| Cash / Share | $9.13 | $8.82 | · | $7.95 | $8.29 | $9.56 | · | $19.15 | $17.45 | $17.24 | · | $16.06 | · | · | |
| EPS (TTM) | $-2.10 | $-0.42 | · | $0.88 | $1.80 | $1.82 | · | $2.83 | $2.86 | $3.21 | · | $2.42 | $2.72 | · |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2026 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $927M | $939M | · | $913M | $899M | $876M | · | $862M | $875M | $900M | · | $853M | $899M | · | |
| Net Income TTM | $-39M | $-8M | · | $17M | $34M | $35M | · | $54M | $55M | $62M | · | $44M | $50M | · | |
| Market Cap | $397M | $312M | · | $521M | $568M | $522M | · | $723M | $862M | $924M | · | $1.12B | · | · | |
| P/E | -10.2 | -40.2 | · | 32.4 | 17.3 | 15.3 | · | 13.4 | 15.8 | 15.1 | · | 24.2 | 23.1 | · | |
| P/S | 0.4 | 0.3 | · | 0.6 | 0.6 | 0.6 | · | 0.8 | 1.0 | 1.0 | · | 1.3 | 1.3 | · | |
| P/B | 0.8 | 0.6 | · | 1.0 | 1.1 | 1.0 | · | 1.4 | 1.7 | 1.8 | · | 2.4 | · | · | |
| P / Tangible Book | 1.4 | 1.1 | · | 2.1 | 2.3 | 2.2 | · | 1.5 | 1.8 | 2.0 | · | 2.6 | · | · | |
| P / Cash Flow | · | 32.0 | · | · | · | 33.7 | · | · | · | 52.2 | · | · | · | · | |
| Earnings Yield | -9.8% | -2.5% | · | 3.1% | 5.8% | 6.6% | · | 7.5% | 6.3% | 6.6% | · | 4.1% | 4.3% | · |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Gelir | $925M | $855M | $921M | $999M | $1.19B |
| Brüt Kâr Marjı % | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% |
| Faaliyet Kâr Marjı % | 4.0% | 7.8% | 10.1% | 10.8% | 14.3% |
| Net Gelir | $11M | $42M | $64M | $69M | $117M |
| Seyreltilmiş Hisse Başı Kâr | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 |
| Metrik | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Cari Oran | 2.2 | 2.0 | 3.5 | 2.7 | 2.3 |
| Cari Oran | 1.2 | 1.3 | 2.8 | 2.0 | 1.5 |
| Metrik | 2026-01-03 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2022-01-01 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $9M | $51M | $56M | $94M | $108M |
Kurumsal Sahipler (13F) 151 dosya · $260.7M toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 25 (-5 önceki Ç'ye göre) | 17 (+8 önceki Ç'ye göre) | 60 (+21 önceki Ç'ye göre) | 30 (-19 önceki Ç'ye göre) | +1.2M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $33.181.935 | 1.554.189 | 12,73% | Hisse senetleri |
| PZENA INVESTMENT MANAGEMENT LLC | $25.739.282 | 1.205.587 | 9,87% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $20.464.402 | 958.520 | 7,85% | Hisse senetleri |
| VANGUARD GROUP INC | $18.340.623 | 934.316 | 7,03% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $17.878.705 | 837.426 | 6,86% | Hisse senetleri |
| Nantahala Capital Management, LLC | $17.295.080 | 810.074 | 6,63% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.405.350 | 487.370 | 3,99% | Hisse senetleri |
| Creative Planning | $8.923.681 | 417.971 | 3,42% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $8.712.637 | 408.086 | 3,34% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.758.099 | 363.377 | 2,98% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $6.047.019 | 283.165 | 2,32% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5.811.641 | 272.208 | 2,23% | Hisse senetleri |
| STATE STREET CORP | $5.577.474 | 261.240 | 2,14% | Hisse senetleri |
| Nuveen, LLC | $5.112.835 | 239.477 | 1,96% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $3.999.880 | 187.348 | 1,53% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $3.855.105 | 180.567 | 1,48% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $3.533.724 | 165.514 | 1,36% | Hisse senetleri |
| MORGAN STANLEY | $3.509.150 | 164.363 | 1,35% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $3.348.427 | 156.835 | 1,28% | Hisse senetleri |
| Allianz Asset Management GmbH | $3.040.219 | 142.399 | 1,17% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $2.949.567 | 138.153 | 1,13% | Hisse senetleri |
| ALGERT GLOBAL LLC | $2.813.033 | 131.758 | 1,08% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $2.631.750 | 123.267 | 1,01% | Hisse senetleri |
| UBS Group AG | $2.474.166 | 115.886 | 0,95% | Hisse senetleri |
| LAZARD ASSET MANAGEMENT LLC | $2.077.590 | 97.311 | 0,80% | Hisse senetleri |
| NORTHERN TRUST CORP | $2.016.870 | 94.467 | 0,77% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $1.552.893 | 72.735 | 0,60% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $1.549.540 | 72.578 | 0,59% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $1.514.569 | 70.940 | 0,58% | Hisse senetleri |
| Empowered Funds, LLC | $1.499.902 | 70.253 | 0,58% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $1.289.691 | 65.700 | 0,49% | Hisse senetleri |
| Bank of New York Mellon Corp | $1.104.521 | 51.734 | 0,42% | Hisse senetleri |
| Quantinno Capital Management LP | $1.072.261 | 50.223 | 0,41% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $967.539 | 45.318 | 0,37% | Hisse senetleri |
| ROYCE & ASSOCIATES LP | $884.039 | 41.407 | 0,34% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $821.975 | 38.500 | 0,32% | Hisse senetleri |
| Assenagon Asset Management S.A. | $815.848 | 38.213 | 0,31% | Hisse senetleri |
| BARCLAYS PLC | $777.141 | 36.400 | 0,30% | Hisse senetleri |
| STRS OHIO | $723.765 | 33.900 | 0,28% | Hisse senetleri |
| Skopos Labs, Inc. | $673.696 | 38.563 | 0,26% | Hisse senetleri |
| HSBC HOLDINGS PLC | $672.758 | 31.960 | 0,26% | Hisse senetleri |
| Invesco Ltd. | $670.775 | 31.418 | 0,26% | Hisse senetleri |
| SEI INVESTMENTS CO | $641.513 | 30.047 | 0,25% | Hisse senetleri |
| XTX Topco Ltd | $625.320 | 29.289 | 0,24% | Hisse senetleri |
| CITADEL ADVISORS LLC | $575.617 | 26.961 | 0,22% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $570.728 | 26.732 | 0,22% | Hisse senetleri |
| Verdad Advisers, LP | $556.552 | 26.068 | 0,21% | Hisse senetleri |
| Inspire Investing, LLC | $512.954 | 29.362 | 0,20% | Hisse senetleri |
| Sanctuary Advisors, LLC | $497.113 | 23.284 | 0,19% | Hisse senetleri |
| Man Group plc | $489.854 | 22.944 | 0,19% | Hisse senetleri |
Aktivistler ve %5+ sahipler 3 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Gull Global Limited, Myron W. Wentz ×11 başvurular | 30 Mart 2026 | 40,10% | Değişiklik | M&A / satış | SEC |
| Gull Holdings, Ltd., Myron W. Wentz, David A. Wentz, Jacquelyn R. Wentz, Bryan Wentz, Annette Wentz, Paul & Jane Meyer Family Foundation, Paul James Meyer, Alice Jane Meyer, Centre Island Properties, Ltd., Waco Boys Club Foundation, Inc., L-K Marketing Group, LLC, Beagle Irrevocable Asset Trust | 23 Mayıs 2008 | · | İlk başvuru | · | SEC |
| Paul & Jane Meyer Family Foundation | 20 Mayıs 2008 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 38 içeriden öğrenenler · 20 yöneticiler · 13 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jim Brown | CEO & PRESIDENT | 24 Temmuz 2025 M | 16.934 | 0 | 0 | $0 |
| Doug G Iiekking | CHIEF FINANCIAL OFFICER | 27 Mayıs 2026 S | 0 | 0 | 1 | $-100.500 |
| Jeffrey Yates | Chief Financial Officer | 28 Ekim 2010 M | 0 | 0 | 0 | $0 |
| Deborah Woo | President of Asia | 08 Eylül 2016 M | 1.479 | 0 | 0 | $0 |
| Fred W Cooper | President and COO | 28 Ekim 2010 M | 0 | 0 | 0 | $0 |
| Walter Noot | CHIEF OPERATING OFFICER | 27 Şubat 2026 M | 9.256 | 0 | 0 | $0 |
| Roy Truett | Chief Operating Officer | 27 Temmuz 2012 M | 0 | 0 | 0 | $0 |
| Kathryn Michelle Armstrong | CHIEF SCIENTIFIC OFFICER | 25 Temmuz 2026 M | 3.471 | 0 | 0 | $0 |
| Peter Benedict | CHIEF INFORMATION OFFICER | 25 Temmuz 2026 M | 422 | 0 | 2 | $-144.236 |
| Brent Neidig | CHIEF COMMERCIAL OFFICER | 16 Haziran 2026 S | 0 | 0 | 3 | $-147.749 |
| Paul A. Jones | CHIEF PEOPLE OFFICER | 08 Haziran 2026 S | 0 | 0 | 2 | $-231.984 |
| Joshua Foukas | CHIEF LEGAL OFFICER | 07 Mayıs 2026 S | 0 | 0 | 2 | $-170.336 |
| David Mulham Mulham | CHIEF SALES OFFICER | 10 Aralık 2025 S | 8.387 | 0 | 1 | $-18.333 |
| Daniel A. Macuga | CHIEF COMMUNICATIONS OFFICER | 02 Mayıs 2024 S | 0 | 0 | 0 | $0 |
| Robert A Sinnott | CHIEF SCIENTIFIC OFFICER | 05 Mart 2024 S | 0 | 0 | 0 | $0 |
| James Bramble | Chief Legal Officer and Sec | 05 Şubat 2018 A | 2.076 | 0 | 0 | $0 |
| Dave Wentz | Co-C.E.O. | 16 Ağustos 2016 M | 384.883 | 0 | 0 | $0 |
| Rick Stambaugh | Chief Information Officer | 17 Aralık 2015 M | 0 | 0 | 0 | $0 |
| Mark H Wilson | E.V.P. of Sales | 28 Ekim 2010 M | 5.000 | 0 | 0 | $0 |
| Bradford Richardson | E.V.P. of Asia Pacific | 25 Şubat 2008 S | 0 | 0 | 0 | $0 |
| Xia Ding | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 8.278 | 0 | 0 | $0 |
| John Turman Fleming | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 5.862 | 0 | 2 | $-78.560 |
| Peggie Pelosi | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 6.061 | 0 | 0 | $0 |
| Scott J Nixon | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 11.445 | 0 | 0 | $0 |
| Frederic J Winssinger | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 9.733 | 0 | 1 | $-38.420 |
| Timothy E Wood | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 11.837 | 0 | 0 | $0 |
| Gilbert A Fuller | Yönetim kurulu üyesi | 23 Temmuz 2026 M | 1.632 | 0 | 3 | $-60.414 |
| Robert Auciaux | Yönetim kurulu üyesi | 09 Mayıs 2022 M | 8.092 | 0 | 0 | $0 |
| Feng Peng | Yönetim kurulu üyesi | 28 Nisan 2021 M | 755 | 0 | 0 | $0 |
| Myron W. Wentz | Yönetim kurulu üyesi | 04 Şubat 2019 S | 9.865.614 | 0 | 0 | $0 |
| Jerry G Mcclain | Yönetim kurulu üyesi | 04 Mart 2016 M | 0 | 0 | 0 | $0 |
| Ronald S Poelman | Yönetim kurulu üyesi | 08 Şubat 2016 A | 0 | 0 | 0 | $0 |
| Denis E Waitley | Yönetim kurulu üyesi | 03 Kasım 2006 M | 0 | 0 | 0 | $0 |
| Gull Global Limited | 10% sahip | 04 Şubat 2019 S | 9.865.614 | 0 | 0 | $0 |
| GULL HOLDINGS LTD | 10% sahip | 01 Nisan 2015 J | 6.491.110 | 0 | 0 | $0 |
| Kevin Guest | · | 27 Şubat 2026 M | 45.381 | 0 | 0 | $0 |
| Donald R. Williams | · | 01 Mayıs 2017 A | · | 0 | 0 | $0 |
| Doug Braun | · | 16 Aralık 2015 M | 0 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 22 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| VFVA · VANGUARD WELLINGTON FUND | 0,11% | 45.046 SH | 19 Ağustos 2026 | Günlük |
| EBIT · Harbor ETF Trust | 0,07% | 367 NS | 31 Temmuz 2026 | N-PORT |
| IWC · iShares Trust | 0,04% | 37.870 SH | 11 Eylül 2026 | Günlük |
| VDC · VANGUARD WORLD FUND | 0,03% | 128.565 SH | 19 Ağustos 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 9.639 SH | 19 Ağustos 2026 | Günlük |
| DFSV · Dimensional ETF Trust | 0,02% | 67.386 NS | 31 Temmuz 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,01% | 23.709 SH | 02 Ekim 2026 | Günlük |
| DFAT · Dimensional ETF Trust | 0,01% | 67.428 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 64.278 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,01% | 5.337 NS | 31 Temmuz 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 1.189 SH | 01 Ekim 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,01% | 42.099 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 283.783 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,00% | 19.278 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 22.756 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 3.720 SH | 03 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 1.784 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 124.681 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 350.035 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 790 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 101.470 SH | 11 Eylül 2026 | Günlük |
| SMLF · iShares Trust | · | 22.964 SH | 11 Eylül 2026 | Günlük |
USNA Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
12 Aylık Fiyat Hedefi
1 analist · 2026-10-01Ortalama hedef $25.00 +68,7%
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| USNA | $355M | 33.5 | 8.3% | 1.2% | 2.0% | 78.3% |
| EPC | $946M | 38.4 | -1.3% | 1.1% | 1.7% | 41.6% |
| BRBR | $4.39B | 21.6 | 16.1% | 9.3% | -72.0% | 33.3% |
| HNST | $291M | -18.4 | -1.9% | -4.2% | -8.8% | 33.3% |
| NUS | · | 3.0 | -14.3% | 10.8% | 22.0% | 69.5% |
| NAGE | $507M | 31.8 | 29.9% | 13.4% | 24.7% | 64.3% |
| NATR | $378M | 20.4 | 5.7% | 4.1% | 12.0% | 72.4% |
| MED | $117M | -6.3 | -36.0% | -4.8% | -9.0% | 71.3% |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.